Gerresheimer AG : Strong Q2, FY 2022 guidance reiterated – a positive set of results
>A convincing Q2 - The company achieved €445m in sales (+17.9% y/y, +13% y/y organic), which was 1-2% better than we and consensus estimated. This was driven by a better organic growth performance. While we do not the impact of inflationary tailwind, yet, this looks strong. Plastics & Devices came in-line, Primary Packaging Glass was better than expected, GAT slightly worse. The adj. EBITDA margin was also better than expected and came in at 20.3% vs 19.2% our estimat...Gerresheimer is a holding company. Through its subsidiaries, Co. manufactures glass and plastic products for the pharma and healthcare industry. Co.'s operates in three divisions: Plastics & Devices, which its product portfolio includes products for the administration of medicines, such as insulin pens, inhalers, and prefillable syringes; Primary Packaging Glass, which produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars; and Life Science Research, which produces laboratory glassware for research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.